INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection.
INH-A21 is an experimental human immune globulin for intravenous infusion (IGIV) derived from donors specifically selected for elevated levels of antibodies against the Staphylococcal fibrinogen-binding proteins, serine aspartate dipeptide repeat G and clumping factor A. Phase II results demonstrated that infusions of INH-A21 were well tolerated and there were no trends for increasing adverse events, or the common morbidities associated with prematurity. Enrollment has been completed in (but no results have been released from) a Phase III human trial testing INH-A21 as a prophylactic agent against staphylococcal infection in very low birth weight infants (500-1250 g).
Bloom
Barry T
BT
Department of Pediatrics, Kansas University School of Medicine--Wichita, Wesley Medical Centre, 550 North Hillside, Wichita, Kansas 67214, USA. barrybloom@aol.com
D018829:Adhesins, Bacterial / Q000276:immunology*; D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D016032:Randomized Controlled Trials as Topic; D013203:Staphylococcal Infections / Q000517:prevention & control*
D018829:Adhesins, Bacterial; D016756:Immunoglobulins, Intravenous; C509820:MSCRAMM proteins, Staphylococcus; C511124:Veronate